Difficulty: Medium
Average Score: 95%
Practice
Indicate the pure opioid antagonist, which has a half-life of 10 hours:
Correct answer
B
Rationale
In this question from the Pharmacology Across the Lifespan ATI exam, the correct answer is B) Naltrexone. Naltrexone is a pure opioid antagonist with a half-life of 10 hours.
Naloxone (A) is a pure opioid antagonist as well, but it has a much shorter half-life of around 30-81 minutes. It is commonly used in emergency situations to reverse opioid overdose due to its rapid onset of action.
Tramadol (C) and Pentazocine (D) are not pure opioid antagonists; they are opioid analgesics with mixed opioid receptor actions. Tramadol is a weak opioid agonist and also inhibits the reuptake of serotonin and norepinephrine, while pentazocine is a partial opioid agonist/antagonist.
Educationally, understanding the characteristics of opioid antagonists is crucial for healthcare professionals, especially when managing opioid overdose or dependence. Knowing the specific properties of each drug, such as half-life, allows for appropriate selection and dosing in clinical practice to achieve the desired therapeutic outcomes. Naltrexone's longer half-life compared to naloxone makes it suitable for sustained opioid receptor blockade in the management of opioid dependence.
Naloxone (A) is a pure opioid antagonist as well, but it has a much shorter half-life of around 30-81 minutes. It is commonly used in emergency situations to reverse opioid overdose due to its rapid onset of action.
Tramadol (C) and Pentazocine (D) are not pure opioid antagonists; they are opioid analgesics with mixed opioid receptor actions. Tramadol is a weak opioid agonist and also inhibits the reuptake of serotonin and norepinephrine, while pentazocine is a partial opioid agonist/antagonist.
Educationally, understanding the characteristics of opioid antagonists is crucial for healthcare professionals, especially when managing opioid overdose or dependence. Knowing the specific properties of each drug, such as half-life, allows for appropriate selection and dosing in clinical practice to achieve the desired therapeutic outcomes. Naltrexone's longer half-life compared to naloxone makes it suitable for sustained opioid receptor blockade in the management of opioid dependence.